Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ampio Pharmaceuticals, Inc.

LOS ANGELES, Oct. 12, 2022 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 17, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (OTC: AMPE) common stock between December […]

On October 12, 2022, Glancy Prongay & Murray LLP issued a reminder to investors regarding the impending deadline to file a lead plaintiff motion in the class action lawsuit against Ampio Pharmaceuticals, Inc. The lawsuit pertains to investors who bought or acquired Ampio common stock between certain dates.

The deadline for filing the lead plaintiff motion is October 17, 2022. Investors who believe they may be eligible to participate in the class action lawsuit should take action before this date to ensure their rights are protected.

Impact on Individuals:

For individuals who have invested in Ampio Pharmaceuticals, Inc., the class action lawsuit could have significant implications. If you are one of these investors, it is crucial to understand your rights and options in this situation. Filing a lead plaintiff motion before the deadline is essential to potentially recover losses suffered as a result of the alleged misconduct.

Impact on the World:

Class action lawsuits against companies like Ampio Pharmaceuticals, Inc. can have broader effects on the financial markets and investor confidence. The outcome of this case could set a precedent for how similar situations are handled in the future, impacting regulations and corporate behavior.

Conclusion:

Investors in Ampio Pharmaceuticals, Inc. should be aware of the upcoming deadline to file a lead plaintiff motion in the class action lawsuit. Taking proactive steps to protect your rights and potential recovery is vital in these circumstances.